当前位置: 首页 >> 检索结果
1723. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
作者: Elizabeth C Smyth.;Georgios Vlachogiannis.;Somaieh Hedayat.;Alice Harbery.;Sanna Hulkki-Wilson.;Massimiliano Salati.;Kyriakos Kouvelakis.;Javier Fernandez-Mateos.;George D Cresswell.;Elisa Fontana.;Therese Seidlitz.;Clare Peckitt.;Jens C Hahne.;Andrea Lampis.;Ruwaida Begum.;David Watkins.;Sheela Rao.;Naureen Starling.;Tom Waddell.;Alicia Okines.;Tom Crosby.;Was Mansoor.;Jonathan Wadsley.;Gary Middleton.;Matteo Fassan.;Andrew Wotherspoon.;Chiara Braconi.;Ian Chau.;Igor Vivanco.;Andrea Sottoriva.;Daniel E Stange.;David Cunningham.;Nicola Valeri.
来源: Gut. 2021年70卷9期1632-1641页
Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cfDNA) of patients enrolled in a randomised first-line phase III clinical trial of chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab in aGEA (NCT00824785).
1724. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
作者: Mathias Jachs.;Lukas Hartl.;Dunja Schaufler.;Christopher Desbalmes.;Benedikt Simbrunner.;Ernst Eigenbauer.;David Josef Maria Bauer.;Rafael Paternostro.;Philipp Schwabl.;Bernhard Scheiner.;Theresa Bucsics.;Albert Friedrich Stättermayer.;Matthias Pinter.;Michael Trauner.;Mattias Mandorfer.;Thomas Reiberger.
来源: Gut. 2021年70卷9期1758-1767页
Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers of systemic inflammation and (2) whether these changes in systemic inflammation predict complications and mortality.
1725. Association between Brachyspira and irritable bowel syndrome with diarrhoea.
作者: Karolina S Jabbar.;Brendan Dolan.;Lisbeth Eklund.;Catharina Wising.;Anna Ermund.;Åsa Johansson.;Hans Törnblom.;Magnus Simren.;Gunnar C Hansson.
来源: Gut. 2021年70卷6期1117-1129页
The incidence of IBS increases following enteric infections, suggesting a causative role for microbial imbalance. However, analyses of faecal microbiota have not demonstrated consistent alterations. Here, we used metaproteomics to investigate potential associations between mucus-resident microbiota and IBS symptoms.
1727. ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.
作者: Liuyi Hao.;Wei Zhong.;Haibo Dong.;Wei Guo.;Xinguo Sun.;Wenliang Zhang.;Ruichao Yue.;Tianjiao Li.;Alexandra Griffiths.;Ali Reza Ahmadi.;Zhaoli Sun.;Zhenyuan Song.;Zhanxiang Zhou.
来源: Gut. 2021年70卷10期1933-1945页
Mitochondrial dysfunction plays a dominant role in the pathogenesis of alcoholic liver disease (ALD); however, the underlying mechanisms remain to be fully understood. We previously found that hepatic activating transcription factor 4 (ATF4) activation was associated with mitochondrial dysfunction in ALD. This study aimed to investigate the function and mechanism of ATF4 in alcohol-induced hepatic mitochondrial dysfunction.
1728. Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods.
作者: W Arnout van Hattem.;Neal Shahidi.;Sergei Vosko.;Imogen Hartley.;Kaushali Britto.;Mayenaaz Sidhu.;Iddo Bar-Yishay.;Scott Schoeman.;David James Tate.;Karen Byth.;David G Hewett.;María Pellisé.;Luke F Hourigan.;Alan Moss.;Nicholas Tutticci.;Michael J Bourke.
来源: Gut. 2021年70卷9期1691-1697页
Large (≥20 mm) sessile serrated lesions (L-SSL) are premalignant lesions that require endoscopic removal. Endoscopic mucosal resection (EMR) is the existing standard of care but carries some risk of adverse events including clinically significant post-EMR bleeding and deep mural injury (DMI). The respective risk-effectiveness ratio of piecemeal cold snare polypectomy (p-CSP) in L-SSL management is not fully known.
1731. Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
作者: Fabian Frost.;Tim Kacprowski.;Malte Rühlemann.;Maik Pietzner.;Corinna Bang.;Andre Franke.;Matthias Nauck.;Uwe Völker.;Henry Völzke.;Marcus Dörr.;Jan Baumbach.;Matthias Sendler.;Christian Schulz.;Julia Mayerle.;Frank U Weiss.;Georg Homuth.;Markus M Lerch.
来源: Gut. 2021年70卷3期522-530页
The intestinal microbiome affects the prevalence and pathophysiology of a variety of diseases ranging from inflammation to cancer. A reduced taxonomic or functional diversity of the microbiome was often observed in association with poorer health outcomes or disease in general. Conversely, factors or manifest diseases that determine the long-term stability or instability of the microbiome are largely unknown. We aimed to identify disease-relevant phenotypes associated with faecal microbiota (in-)stability.
1733. Mandatory preprocedure testing for SARS-CoV-2 for all-comers may not be required for resuming endoscopic services amidst the ongoing COVID-19 pandemic.
作者: Soumya Jagannath.;Ashish Agarwal.;Deepak Gunjan.;Samir Mohindra.;Vishal Sharma.;Sudipta Dhar Chowdhury.;Sanjeev Sachdeva.;Vivek A Saraswat.;Rakesh Kochhar.;Anoop Saraya.; .
来源: Gut. 2021年70卷9期1805-1806页 1734. Pain patterns in chronic pancreatitis: a nationwide longitudinal cohort study.
作者: Marinus A Kempeneers.;Yama Issa.;Robert C Verdonk.;Marco Bruno.;P Fockens.;Harry van Goor.;Eline Alofs.;Thomas L Bollen.;Stefan Bouwense.;Anne S H M van Dalen.;Susan van Dieren.;Hendrik M van Dullemen.;Erwin-Jan van Geenen.;Chantal Hoge.;Jeanin E van Hooft.;Liesbeth M Kager.;Yolande Keulemans.;Lynn E Nooijen.;Jan-Werner Poley.;Tom C J Seerden.;Adriaan Tan.;Willem Thijs.;Robin Timmer.;Frank Vleggaar.;Ben Witteman.;Usama Ahmed Ali.;Marc G Besselink.;Marja A Boermeester.;Hjalmar C van Santvoort.; .
来源: Gut. 2021年70卷9期1724-1733页
Pain in chronic pancreatitis is subdivided in a continuous or intermittent pattern, each thought to represent a different entity, requiring specific treatment. Because evidence is missing, we studied pain patterns in a prospective longitudinal nationwide study.
1738. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
作者: Runze Shang.;Xinhua Song.;Pan Wang.;Yi Zhou.;Xinjun Lu.;Jingxiao Wang.;Meng Xu.;Xinyan Chen.;Kirsten Utpatel.;Li Che.;Binyong Liang.;Antonio Cigliano.;Matthias Evert.;Diego F Calvisi.;Xin Chen.
来源: Gut. 2021年70卷9期1746-1757页
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of cabozantinib, either alone or in combination, in vitro and in vivo.
1740. Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts.
作者: Hugo A Penny.;Suneil A Raju.;Michelle S Lau.;Lauren Js Marks.;Elisabeth Mr Baggus.;Julio C Bai.;Gabrio Bassotti.;Hetty J Bontkes.;Antonio Carroccio.;Mihai Danciu.;Mohammad H Derakhshan.;Arzu Ensari.;Azita Ganji.;Peter H R Green.;Matt W Johnson.;Sauid Ishaq.;Benjamin Lebwohl.;Adam Levene.;Roxana Maxim.;Hamid Mohaghegh Shalmani.;Mohammad Rostami-Nejad.;David Rowlands.;Irene A Spiridon.;Amitabh Srivastava.;Umberto Volta.;Vincenzo Villanacci.;Graeme Wild.;Simon S Cross.;Kamran Rostami.;David S Sanders.
来源: Gut. 2021年70卷5期876-883页
We aimed to determine the predictive capacity and diagnostic yield of a 10-fold increase in serum IgA antitissue transglutaminase (tTG) antibody levels for detecting small intestinal injury diagnostic of coeliac disease (CD) in adult patients.
|